This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Ninlaro click here.

NINLARO ixazomib capsules

Extended Efficacy.
Extended Possibilities.

NINLARO (ixazomib) + Rd significantly extends PFS vs Rd alone and offers
a manageable side effect profile with the convenience of an all-oral regimen1,2

NINLARO: the first and only oral proteasome inhibitor licensed in combination with lenalidomide and dexamethasone (Rd) for treatment of adult patients with multiple myeloma who have received at least 1 prior therapy2

Adding oral NINLARO to Rd extends PFS across a broad group of patients compared with Rd alone1,2

A long-term treatment approach in RRMM should address efficacy, tolerability and patient burden.3 However, long-term treatment in MM remains a challenge with a number of current therapeutic options.4 Adding oral NINLARO to Rd extends PFS across a broad group of patients irrespective of cytogenetic risk, compared with Rd alone.1

Patient support

Takeda Oncology has developed a range of information and support tools designed for patients prescribed NINLARO

Click here to find out more about the support offered to NINLARO patients